Attached files

file filename
EX-99 - EXHIBIT 99.1 - AtheroNova Inc.ex99-1.htm


 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________________

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report:

 

(Date of earliest event reported)

 

August 13, 2013

 

____________________________

 

ATHERONOVA INC.

(Exact name of registrant as specified in charter)

 

Delaware

(State or other Jurisdiction of Incorporation or Organization)

 

000-52315

(Commission File Number)

 

20-1915083

(IRS Employer Identification No.)

     
 

2301 Dupont Drive, Suite 525

Irvine, CA 92612

(Address of Principal Executive Offices and zip code)

 

 

(949) 476-1100

(Registrant’s telephone
number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ] Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

 

 



 

 

 

Item 8.01.

Other Events.

 

On August 13, 2103, Thomas W. Gardner, the Registrant’s Chief Executive Officer, commenced small group presentations regarding the Registrant. A copy of Mr. Gardner’s presentation is being furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits

   
(d) Exhibits.

 

The following exhibits are filed herewith:

 

 

Exhibit

Number

Description
     
 

99.1

AtheroNova Inc. Company Presentation.*

 

* Furnished, not filed.

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

AtheroNova Inc.

 
       
        
Date: August 13, 2013 By: /s/ Mark Selawski  
   

Mark Selawski

 
   

Chief Financial Officer & Secretary

 

 

 

 

3